Introduction {#H1-1-ZOI180173}
============

The increasing worldwide use of psychotropic drugs and their application beyond licensed indications has attracted close scrutiny.^[@zoi180173r1],[@zoi180173r2],[@zoi180173r3]^ At least 1 in 6 adults in the United States is prescribed psychotropic medication,^[@zoi180173r4]^ and high levels of psychotropic drug use are demonstrated in several vulnerable groups, including elderly individuals,^[@zoi180173r5]^ people with dementia,^[@zoi180173r6]^ children and adolescents,^[@zoi180173r7]^ and those with neurodevelopmental disorders, including autism^[@zoi180173r8]^ and intellectual disability.^[@zoi180173r9],[@zoi180173r10]^ Although undoubtedly of benefit to many individuals, psychotropic drugs are associated with significant adverse drug events that can affect quality of life and result in additional service costs.^[@zoi180173r11],[@zoi180173r12]^ Spending on psychotropic drugs continues to grow^[@zoi180173r13],[@zoi180173r14]^ and a high rate of nonadherence leads to significant waste.^[@zoi180173r15]^

Medication optimization is a broad approach aimed at ensuring the safest and most effective use of medications.^[@zoi180173r16]^ The concept has gained traction and has been applied to psychotropic drug prescribing, for example, in the Centers for Medicare & Medicaid Services' recent efforts to reduce inappropriate antipsychotic prescribing in nursing homes.^[@zoi180173r17]^

Medication optimization encompasses a range of strategies that may be used throughout the medication pathway, including educational interventions, formularies that identify drugs with the greatest perceived overall value, consensus guidelines to direct best practices, benchmarking of prescription rates, and decision aids developed to enable patients to take a more active role in treatment decisions based on their values and preferences. After a drug has been prescribed, optimization includes support for adherence and medication reconciliation. Medication review, a structured and critical evaluation of medication, might have a role in medication optimization, maximizing therapeutic efficacy, mitigating adverse events, and identifying opportunities for decreasing prescribing.^[@zoi180173r18]^ In this systematic review we describe the content and delivery of focused psychotropic medication review and synthesize the evidence for its contribution to medication optimization.

Methods {#H1-2-ZOI180173}
=======

A literature search was conducted in Medline, PsycINFO, EMBASE, and CINAHL Plus from inception to February 2018 to identify peer-reviewed original research articles that reported the effect of focused psychotropic medication review on medication optimization outcomes. Search terms included "drug utilization review" (and synonyms) combined with "psychotropic drugs" (and synonyms) (see eTable 1 in the [Supplement](#note-ZOI180173-1-s){ref-type="supplementary-material"} for an example of full search strategy). Psychotropic drugs were defined in accordance with the World Health Organization Anatomical Therapeutic Chemical Classification System.^[@zoi180173r19]^ Medication review was defined as a structured critical evaluation of medication with an aim to improve safety, efficacy, or cost-effectiveness. Optimization outcomes were intentionally broad. Any study design was included and there were no restrictions on population, setting, language, or date of publication. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses ([PRISMA](http://www.equator-network.org/reporting-guidelines/prisma/)) reporting guideline. The protocol was registered prospectively with PROSPERO (registration No. CRD42017077244).

To limit potential confounding, studies were excluded if they reported a comprehensive medication review (including multiple classes of medication) or conducted a medication review as part of a multimodal intervention where the effect of medication review on reported outcomes could not be distinguished. Short reports, research letters, dissertations, and conference abstracts were not included but prompted a search for full-length articles. Reference lists of included studies and previously published reviews in the field were extensively hand searched to find articles not identified in the database search. The citations of included articles were identified using Google Scholar and considered for relevance.

After exclusion of duplicate records, the titles of all articles were screened by one of us (R.S.), and a randomly selected sample was independently reviewed by another of us (E.B.). They independently reviewed abstracts of remaining studies (and later selected full text) against inclusion and exclusion criteria, with any discrepancies resolved by consensus or discussion with a third member of the research team.

Study quality was rated independently by 2 of us (R.S. and E.B.) using the relevant quality checklist published by the National Institutes of Health^[@zoi180173r20]^ along with a descriptive evaluation of the limitations of each article. Studies received an overall grading of poor, fair, or good quality based on the proportion of applicable checklist items that were met (poor, \<30% of items; fair, 30%-60%; good, \>60%). Results of the quality appraisal were used to inform a structured evidence synthesis, with higher-quality studies given precedence.

Data were extracted from studies and used to populate summary tables. Type of medication review was classified according to the Task Force on Medicines Partnership and the National Collaborative Medicines Management Services Program (level 1, prescription review; level 2, treatment review; level 3, clinical medication review).^[@zoi180173r18]^ Outcomes were grouped according to theme, allowing comparison between different studies. Measures of psychotropic drug optimization could include changes in medication-related variables, clinical efficacy or adverse drug events, participant-reported outcomes, or economic evaluations. Additional data were sought by contacting authors of included studies, where indicated.

Results were summarized narratively. Numerical data were extracted and, where comparable, means and 95% CIs were calculated around summary statistics. Odds ratios for comparable outcomes reported in randomized clinical trials (RCTs) were entered into a meta-analysis using the *metan* command in Stata, version 14^[@zoi180173r21]^ and using a random-effects model. The *I*^2^ statistic was used to estimate statistical heterogeneity between studies.^[@zoi180173r22]^

Results {#H1-3-ZOI180173}
=======

The search yielded a total of 9485 articles, of which 27 met inclusion criteria ([Figure 1](#zoi180173f1){ref-type="fig"}). The results of 1 study were reported in 2 articles.^[@zoi180173r23],[@zoi180173r24]^ Four studies were cluster RCTs (n = 712 participants)^[@zoi180173r23],[@zoi180173r24],[@zoi180173r25],[@zoi180173r26],[@zoi180173r27]^ and the remaining 22 were before-after study designs (n = 7844 participants).^[@zoi180173r28],[@zoi180173r29],[@zoi180173r30],[@zoi180173r31],[@zoi180173r32],[@zoi180173r33],[@zoi180173r34],[@zoi180173r35],[@zoi180173r36],[@zoi180173r37],[@zoi180173r38],[@zoi180173r39],[@zoi180173r40],[@zoi180173r41],[@zoi180173r42],[@zoi180173r43],[@zoi180173r44],[@zoi180173r45],[@zoi180173r46],[@zoi180173r47],[@zoi180173r48],[@zoi180173r49]^ Studies were conducted in North America (15 studies),^[@zoi180173r28],[@zoi180173r30],[@zoi180173r31],[@zoi180173r32],[@zoi180173r33],[@zoi180173r35],[@zoi180173r36],[@zoi180173r37],[@zoi180173r39],[@zoi180173r42],[@zoi180173r43],[@zoi180173r46],[@zoi180173r47],[@zoi180173r48],[@zoi180173r49]^ Europe (10 studies)^[@zoi180173r23],[@zoi180173r25],[@zoi180173r26],[@zoi180173r27],[@zoi180173r29],[@zoi180173r38],[@zoi180173r40],[@zoi180173r41],[@zoi180173r44],[@zoi180173r45]^ and Australasia (1 study).^[@zoi180173r34]^ A total of 19 studies^[@zoi180173r23],[@zoi180173r26],[@zoi180173r27],[@zoi180173r28],[@zoi180173r29],[@zoi180173r30],[@zoi180173r31],[@zoi180173r32],[@zoi180173r33],[@zoi180173r34],[@zoi180173r36],[@zoi180173r37],[@zoi180173r39],[@zoi180173r40],[@zoi180173r41],[@zoi180173r43],[@zoi180173r46],[@zoi180173r47],[@zoi180173r48]^ were conducted in institutional settings and reported psychotropic medication review of people with intellectual disability (9 studies; 1054 participants)^[@zoi180173r28],[@zoi180173r29],[@zoi180173r30],[@zoi180173r31],[@zoi180173r32],[@zoi180173r33],[@zoi180173r34],[@zoi180173r35],[@zoi180173r36]^ or those with dementia (6 studies; 3664 participants).^[@zoi180173r23],[@zoi180173r37],[@zoi180173r38],[@zoi180173r39],[@zoi180173r40],[@zoi180173r41]^ Meta-analysis included 3 studies^[@zoi180173r28],[@zoi180173r30],[@zoi180173r34]^ (n = 652 participants).

![PRISMA Flowchart](jamanetwopen-1-e183750-g001){#zoi180173f1}

Details of included studies are in eTable 2 in the [Supplement](#note-ZOI180173-1-s){ref-type="supplementary-material"}. When assessed against objective criteria, most research was at medium to high risk of bias. Key methodological problems encountered across studies were single group design, reporting bias, lack of measures of implementation fidelity, lack of objective and validated outcome measures, short follow-up times, and limited (or absent) statistical analysis. Several studies made claims that were not supported by the findings.

Content and Delivery of Psychotropic Medication Review {#H2-1-ZOI180173}
------------------------------------------------------

The focused psychotropic medication reviews fell into 3 major categories. The first was one-off medication review, usually undertaken by a single professional and including a single class of psychotropic drug.^[@zoi180173r23],[@zoi180173r25],[@zoi180173r38],[@zoi180173r40],[@zoi180173r41],[@zoi180173r42],[@zoi180173r43],[@zoi180173r44],[@zoi180173r45]^ The second model was a longitudinal program of regular medication review, often by a multidisciplinary team who reviewed the participant's psychotropic drug regimen in a series of meetings.^[@zoi180173r26],[@zoi180173r27],[@zoi180173r28],[@zoi180173r29],[@zoi180173r30],[@zoi180173r31],[@zoi180173r32],[@zoi180173r33],[@zoi180173r34],[@zoi180173r35],[@zoi180173r36],[@zoi180173r37],[@zoi180173r39]^ The third type of focused psychotropic medication review was 2-stage, in which those at high risk of suboptimal drug therapy were identified using a rule applied to the electronic patient record and then directed to clinician medication review.^[@zoi180173r46],[@zoi180173r47],[@zoi180173r48],[@zoi180173r49]^ Within this categorization, the configuration of focused psychotropic medication review varied considerably from remote review by a third party to detailed medication review with access to the patient's full clinical notes and the patient's direct input to the process ([Table 1](#zoi180173t1){ref-type="table"}).^[@zoi180173r18],[@zoi180173r23],[@zoi180173r24],[@zoi180173r25],[@zoi180173r26],[@zoi180173r27],[@zoi180173r28],[@zoi180173r29],[@zoi180173r30],[@zoi180173r31],[@zoi180173r32],[@zoi180173r33],[@zoi180173r34],[@zoi180173r35],[@zoi180173r36],[@zoi180173r37],[@zoi180173r38],[@zoi180173r39],[@zoi180173r40],[@zoi180173r41],[@zoi180173r42],[@zoi180173r43],[@zoi180173r44],[@zoi180173r45],[@zoi180173r46],[@zoi180173r47],[@zoi180173r48],[@zoi180173r49]^ Medication reviews were most often organized according to local protocols, but specific conduct of the medication review was commonly not reported.

###### Focused Psychotropic Medication Review---Summary of Content and Delivery

  Source                                                                                 Participants, Setting                                                            Psychotropic Drugs Reviewed          Professionals Involved                                                                   Patient or Patient Representative Involvement   Review Delivery                                                                                                                                                                                                                                                                                                                                        Guidelines and Instruments Used                                                                                                                                                                                                 Review Level^[@zoi180173r18]^
  -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ------------------------------------ ---------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  **One-Off Medication Reviews**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Ballard et al,^[@zoi180173r23]^ 2016, and Ballard et al,^[@zoi180173r24]^ 2017         277 People with dementia, nursing home                                           Antipsychotic drugs                  Physician                                                                                NR                                              General practitioner or psychiatrist performed antipsychotic review using clinical guidelines to determine appropriateness and direct withdrawal attempts                                                                                                                                                                                              NICE dementia guidelines; Alzheimer Society guidelines                                                                                                                                                                          CD
  Moncrieff et al,^[@zoi180173r25]^ 2016                                                 60 People with severe mental illness, community                                  Antipsychotic drugs                  Physician and care coordinator (nurse, social worker, occupational therapist)            Yes: patient                                    Patients used a medication review tool with their care coordinator prior to a psychiatrist appointment; the tool incorporated perceived benefits and disadvantages of antipsychotic drugs and desired changes, which could be discussed with the prescriber                                                                                            Medication Review Tool (developed for the study)                                                                                                                                                                                3
  Gallimore et al,^[@zoi180173r42]^ 2016                                                 144 Children and adults with mental illness, community                           Psychotropic drugs                   Pharmacist                                                                               No                                              Pharmacist reviewed medication record and electronic health record 1-3 mo after psychiatrist appointment; drug monitoring reviewed against best practice guidelines and potential for drug-drug interactions assessed using drug interaction database; recommendations sent to prescriber                                                              American Psychiatric Association Practice Guidelines, Mount Sinai Conference Consensus recommendations, Development Conference on Antipsychotic Drugs and Obesity and Diabetes guidelines used to define monitoring standards   1
  Prentice and Wright,^[@zoi180173r41]^ 2014                                             3165 Older adults, nursing home                                                  Antipsychotic drugs                  Pharmacist, care staff, physician                                                        No                                              Pharmacist reviewed symptoms, adverse effects, and medication-related information, discussed with care staff, and made recommendations to physician                                                                                                                                                                                                    NICE guidelines, standard data collection form to inform decision making                                                                                                                                                        2
  Gemelli et al,^[@zoi180173r43]^ 2016                                                   34 Older adults, nursing home                                                    Sedative and hypnotic drugs          Pharmacist                                                                               No                                              Pharmacist reviewed medication records and, where indicated, made recommendations (dose reduction, drug discontinuation, reevaluation of symptoms, or switch to alternative drugs) to the prescriber                                                                                                                                                   No formal guidelines or standard instruments used in this medication review                                                                                                                                                     1
  Child et al,^[@zoi180173r38]^ 2012                                                     70\) People with dementia, care home or community                                Antipsychotic drugs                  Pharmacist                                                                               Yes: patient and family                         Pharmacist reviewed medication record and clinical records and discussed changes to antipsychotic prescribing with general practitioner, care staff, and patient (±family)                                                                                                                                                                             No formal guidelines or standard instruments used in this medication review                                                                                                                                                     3
  Johnson et al,^[@zoi180173r44]^ 2012                                                   2849 Adults, community                                                           Antidepressant drugs                 Physician                                                                                Yes: patient                                    Physician completed face-to-face medication review                                                                                                                                                                                                                                                                                                     No formal guidelines or standard instruments used in this medication review                                                                                                                                                     3
  Napolitano et al,^[@zoi180173r45]^ 2012                                                32 Adults, community                                                             Antidepressant drugs                 Nurse                                                                                    Yes: patient                                    Nurse prescriber completed face-to-face medication review including illness- and medication-related variables, patient understanding and beliefs, and risk assessment                                                                                                                                                                                  Patient Health Questionnaire, Generalized Anxiety Disorder Scale, Work and Social Adjustment Scale, Phobic Scale                                                                                                                3
  **Regular Medication Review Programs**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Jordan et al,^[@zoi180173r26]^ 2015                                                    41 Elderly, nursing home                                                         Psychotropic drugs                   Nurse                                                                                    Yes: patient and family                         Monthly nurse review according to a checklist incorporating psychotropic drug adverse effects other and unmet needs; completed with patient and acting as a prompt to further activity, including prescriber medication review                                                                                                                         West Wales Adverse Drug Reaction profile                                                                                                                                                                                        3
  Patterson et al,^[@zoi180173r27]^ 2010                                                 334 Elderly individuals, nursing home                                            Psychotropic drugs                   Pharmacist, physician                                                                    Yes: patient and family                         Monthly pharmacists reviewed patient records and interviewed patients and family to identify drug-related problems and used an algorithm to identify potentially inappropriate psychotropic drug prescribing; pharmacist recommendations discussed with physician and drug decisions made                                                              Fleetwood algorithm for appropriateness of psychotropic drug prescription                                                                                                                                                       3
  Bach et al,^[@zoi180173r37]^ 2017                                                      20 People with dementia, nursing home                                            Antipsychotic drugs                  Pharmacist                                                                               No                                              Monthly pharmacist screened medication charts against criteria for appropriate antipsychotic use and made recommendations to the physician                                                                                                                                                                                                             Antipsychotic Use Survey Tool was used to determine appropriate and inappropriate antipsychotic prescribing                                                                                                                     1
  Morrison,^[@zoi180173r40]^ 2009                                                        22 Older adults, nursing home                                                    Antipsychotic drugs                  General practitioner                                                                     NR[^a^](#zoi180173t1n1){ref-type="table-fn"}    General practitioner completed structured review of antipsychotic prescribing supported by a checklist based on NICE guidance every 6 mo                                                                                                                                                                                                               No formal guidelines or standard instruments used in this medication review                                                                                                                                                     CD
  Dahl et al,^[@zoi180173r39]^ 2008                                                      110 People with dementia, long-term care                                         Psychotropic drugs                   Nurse, social worker, pharmacist, physician                                              Yes: family                                     Multidisciplinary team gather information using a standardized psychotropic assessment form covering symptoms, behavior, adverse effects, and patient and family concerns every 6 mo; followed by a multidisciplinary team meeting where recommendations to optimize prescribing are agreed and sent to the prescriber                                 Psychotropic Assessment Tool                                                                                                                                                                                                    3
  Branford,^[@zoi180173r29]^ 1996                                                        198 People with intellectual disability, institution                             Antipsychotic drugs                  Nurse, psychiatrist, pharmacist                                                          No                                              Regular multidisciplinary meeting to review diagnosis, behavior, and medication prescribing; prescribing decisions made by consensus                                                                                                                                                                                                                   Aberrant Behavior Checklist, Psychopathology Instrument for Mentally Retarded Adults, Reiss screen                                                                                                                              2
  Bisconer et al,^[@zoi180173r28]^ 1995                                                  80 People with intellectual disability, institution                              Psychotropic drugs                   Physician, pharmacist, psychologist, nurse, other professional staff, lay participants   No                                              Multidisciplinary meetings to discuss presentation, drug adverse effects, and broader treatment plan every 6 mo; changes to prescribing made by consensus                                                                                                                                                                                              Standard report (no validated instruments)                                                                                                                                                                                      2
  Jauernig et al,^[@zoi180173r34]^ 1995                                                  25 People with intellectual disability, institution                              Psychotropic drugs                   Pharmacist, physician, psychologist, care staff, clinical manager                        No                                              Multidisciplinary meetings every 2 mo to discuss presentation and progress, review data collected on standardized forms, and agree drug recommendations to be made to treating physician                                                                                                                                                               Behavior monitoring record forms, Aberrant Behavior Checklist, adverse effect monitoring checklist                                                                                                                              2
  Glaser et al,^[@zoi180173r32]^ 1986                                                    28 People with intellectual disability, institution                              Antipsychotic drugs                  Physician, nurse, pharmacist, psychologist, care staff, administrator                    No                                              Monthly multidisciplinary team review including indication for medication, symptoms, alternative treatments, and medication response; recommendations made                                                                                                                                                                                             No formal guidelines or standard instruments used in this medication review                                                                                                                                                     2
  Marcoux,^[@zoi180173r36]^ 1985                                                         255 People with intellectual disability, institution                             Psychotropic drugs                   Physician, psychologist, nurse, pharmacist                                               No                                              Multidisciplinary meetings every 3 mo to review symptoms, adverse effects, and other information and inform medication decisions                                                                                                                                                                                                                       Standard data sheets completed                                                                                                                                                                                                  2
  Lepler et al,^[@zoi180173r35]^ 1993                                                    12 People with intellectual disability, community                                Psychotropic drugs                   Nurse, psychologist, care staff, physician                                               Yes: family or advocate                         Multidisciplinary review every 3 mo of clinical presentation, medication response, and adverse effects, laboratory monitoring, alternative interventions, and other factors leading to drug recommendations based on team consensus; final decisions are a combination of team recommendations, patient and family preference, and physician opinion   No formal guidelines or standard instruments used in this medication review                                                                                                                                                     3
  Ferguson et al,^[@zoi180173r31]^ 1982                                                  97 People with intellectual disability, institution                              Antipsychotic drugs                  Physician, psychologist, social worker, nurse, pharmacist, care staff                    No                                              Monthly multidisciplinary review of target symptoms and medication adverse effects with data (counts of challenging behavior) used to direct drug dose changes according to a specified protocol                                                                                                                                                       No formal guidelines or standard instruments used in this medication review                                                                                                                                                     2
  Inoue,^[@zoi180173r33]^ 1982                                                           251 People with intellectual disability, institution                             Psychotropic drugs                   Pharmacist, physician, nurse, care staff                                                 No                                              Monthly pharmacist collected data on patient condition, response to treatment, drug adverse effects presented at multidisciplinary meetings; pharmacist recommendations for treatment discussed and accepted or declined                                                                                                                               Standard data forms used to inform reviews                                                                                                                                                                                      2
  Ellenor et al,^[@zoi180173r30]^ 1977                                                   208 People with intellectual disability, institution                             Psychotropic drugs                   Physician, pharmacist, nurse, psychologist, sociologist, therapist                       No                                              Pharmacist collected data every 3 mo on drug history, interactions, adverse effects, clinical presentation, response to treatment, and made recommendations that were discussed and accepted or declined at multidisciplinary meetings                                                                                                                 Data collected on a standard form                                                                                                                                                                                               2
  **Electronic Identification of Prescribing Followed by Clinician Medication Review**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Donat,^[@zoi180173r46]^ 2006                                                           People with mental illness, hospital[^a^](#zoi180173t1n1){ref-type="table-fn"}   Psychotropic drugs (as-needed use)   Psychiatrist, psychologist                                                               No                                              Automated identification of patients receiving as-needed medication ≥3 times a week followed by case review by psychiatrist and psychologist using a semistructured form to guide decisions; further review by a senior management committee in some cases                                                                                             Local guidelines                                                                                                                                                                                                                2
  Seltzer et al,^[@zoi180173r49]^ 2000                                                   Adults and children, community[^a^](#zoi180173t1n1){ref-type="table-fn"}         Sedatives and hypnotics              Physician                                                                                NR[^a^](#zoi180173t1n1){ref-type="table-fn"}    Automated identification of patients prescribed long-term or high-dose sedatives or intraclass polypharmacy followed by letter to prescriber to prompt review of medication (this stage of medication review not well described)                                                                                                                       No formal guidelines or standard instruments used in this medication review                                                                                                                                                     1
  Craig et al,^[@zoi180173r47]^ 1984                                                     People with mental illness, hospital[^a^](#zoi180173t1n1){ref-type="table-fn"}   Psychotropic drugs                   Physician                                                                                No                                              Automated identification of patients receiving high or low drug doses or polypharmacy followed by clinical review by 2 physicians to judge appropriateness of prescribing; further review by senior physicians when agreement not reached                                                                                                              No formal guidelines or standard instruments used in this medication review                                                                                                                                                     2
  Laska et al,^[@zoi180173r48]^ 1980                                                     People with mental illness, hospital[^a^](#zoi180173t1n1){ref-type="table-fn"}   Psychotropic drugs                   Physicians                                                                               No                                              Automated identification of patients receiving high or low drug doses or polypharmacy followed by drug review by 2 physicians and consultation with a peer group, if necessary                                                                                                                                                                         No formal guidelines or standard instruments used in this medication review                                                                                                                                                     2

Abbreviations: CD, cannot determine; NICE, National Institute for Health and Care Excellence; NR, not reported.

No. of participants not given.

Studies reported review of antipsychotic drugs (9 studies),^[@zoi180173r23],[@zoi180173r25],[@zoi180173r29],[@zoi180173r31],[@zoi180173r32],[@zoi180173r37],[@zoi180173r38],[@zoi180173r40],[@zoi180173r41]^ sedatives and hypnotics (2 studies),^[@zoi180173r43],[@zoi180173r49]^ antidepressants (2 studies),^[@zoi180173r44],[@zoi180173r45]^ or several psychotropic drug classes concomitantly (13 studies).^[@zoi180173r26],[@zoi180173r27],[@zoi180173r28],[@zoi180173r30],[@zoi180173r33],[@zoi180173r34],[@zoi180173r35],[@zoi180173r36],[@zoi180173r39],[@zoi180173r42],[@zoi180173r46],[@zoi180173r47],[@zoi180173r48]^ A range of medical and other health professionals were involved in medication reviews, with the most consistent representation being by clinical pharmacists. A minority of reviews incorporated involvement of the patient or family or advocate.

Several studies reported standardized methods of data collection that were used to inform medication review, although few used validated instruments to measure clinical variables. Most focused psychotropic medication reviews relied on implicit decision making and clinician judgment, rather than explicit measures of drug appropriateness and best practice guidelines.

Medication-Related Outcomes of Psychotropic Medication Review {#H2-2-ZOI180173}
-------------------------------------------------------------

A measure of change in psychotropic drug prescribing after focused psychotropic medication review was the most consistently reported medication-related outcome. Ballard et al,^[@zoi180173r23]^ Jordan et al,^[@zoi180173r26]^ and Patterson et al^[@zoi180173r27]^ report a significant effect of focused psychotropic medication review in reducing psychotropic drug prescribing in cognitively impaired elderly residents of nursing homes (pooled odds ratio, 0.24; 95% CI, 0.14-0.39) ([Figure 2](#zoi180173f2){ref-type="fig"}).^[@zoi180173r23],[@zoi180173r25],[@zoi180173r26],[@zoi180173r27]^ Additional data obtained from Moncrieff et al^[@zoi180173r25]^ showed a nonsignificant tendency to greater change in antipsychotic medication among adults with severe mental illness undergoing outpatient focused psychotropic medication review conducted by their usual psychiatrist than among those receiving standard care (odds ratio, 0.38; 95% CI, 0.12-1.19).

![Forest Plot Showing Odds of Change in Antipsychotic Medication and Odds of Reduction in Psychotropic Medication Following Focused Medication Review vs Treatment as Usual\
The size of the data markers is determined by weight from random-effects analysis. OR indicates odds ratio.](jamanetwopen-1-e183750-g002){#zoi180173f2}

One-off focused psychotropic medication review was associated with mean of 34.0% (95% CI, 32.9%-35.2%) of participants having a change in medication prescription ([Figure 3](#zoi180173f3){ref-type="fig"}A).^[@zoi180173r29],[@zoi180173r37],[@zoi180173r38],[@zoi180173r40],[@zoi180173r41],[@zoi180173r43],[@zoi180173r44],[@zoi180173r45],[@zoi180173r49]^ Four before-after studies report the effect of focused medication review on antipsychotic drugs prescribed for behavioral and psychological symptoms of dementia.^[@zoi180173r37],[@zoi180173r38],[@zoi180173r40],[@zoi180173r41]^ These reviews, conducted by either a pharmacist^[@zoi180173r37],[@zoi180173r38],[@zoi180173r41]^ or general practitioner,^[@zoi180173r40]^ were associated with a reduction or discontinuation of antipsychotic drugs in 20% to 61% of participants.

![Proportion of Participants of Included Studies With Change in Psychotropic Medication Prescription\
A, After one-off medication review. B, After medication review program. The size of the data markers is based on the number of participants, and the error bars indicate 95% CIs.](jamanetwopen-1-e183750-g003){#zoi180173f3}

Gemelli et al^[@zoi180173r43]^ investigated pharmacist review of sedative and hypnotic medication in elderly people living in a nursing home. The intervention was associated with dose reduction or discontinuation in 49% of the sample by follow-up at 3 months.

Two before-after studies addressed the effect on drug prescribing of clinical review of long-term antidepressant drug therapy in community-dwelling adults. One large Scottish study (N = 2849) found that 28.5% of individuals taking antidepressants had a medication change after in-person review by their general practitioner, with most changes being drug discontinuation or dose reduction.^[@zoi180173r44]^ A similar study, conducted on a much smaller scale (N = 32), reported that medication change followed just above half of the medication reviews conducted by a specialist nurse prescriber.^[@zoi180173r45]^

The 4 studies that used electronic prescribing records to identify prescribing that fell outside defined guidelines to generate alerts, prompting clinician-focused psychotropic medication review, all report that the process was associated with improved rates of guideline-compliant prescribing.^[@zoi180173r46],[@zoi180173r47],[@zoi180173r48],[@zoi180173r49]^

Several studies report the association of a program of multidisciplinary medication review with psychotropic prescribing. In all but 1 case, these studies were conducted before 2000 and focused on the use of psychotropic drugs for challenging behavior in adults with intellectual disability, most of whom were receiving long-term institutional care.^[@zoi180173r28],[@zoi180173r29],[@zoi180173r30],[@zoi180173r31],[@zoi180173r32],[@zoi180173r33],[@zoi180173r34],[@zoi180173r35],[@zoi180173r36]^ The quality of these studies is poor to fair, yet together they report results of psychotropic medication review of a relatively homogeneous group of more than 1000 adults (most with severe to profound intellectual disability and behavior disturbance living in large institutional facilities), with follow-up of between 6 months and 4 years. [Figure 3](#zoi180173f3){ref-type="fig"}B^[@zoi180173r28],[@zoi180173r31],[@zoi180173r32],[@zoi180173r33],[@zoi180173r34],[@zoi180173r35]^ shows the proportion of participants in these studies undergoing a reduction or change in psychotropic medication after the review programs, where this metric is given or can be extrapolated from the published results (mean proportion changing prescription, 57.6%; 95% CI, 53.2%-62.0%). These studies demonstrate the association of focused psychotropic medication review with medication change in a potentially overmedicated group; most changes were dose reductions or discontinuations.

Studies that do not report the proportion of participants with medication change still report an association with either reduction of overall psychotropic prescribing at the group level^[@zoi180173r30],[@zoi180173r36]^ or reduced rates of polypharmacy.^[@zoi180173r28],[@zoi180173r34]^ Ellenor and Frisk^[@zoi180173r30]^ demonstrate a reduction of 37% in psychotropic prescription items during the course of a 2-year regular medication review and Marcoux^[@zoi180173r36]^ found that their process of psychotropic medication review was associated with a mean dose reduction of 17% in individuals receiving antipsychotic drugs. An exception to these findings is a more recent study by Dahl et al,^[@zoi180173r39]^ who report the results of a thorough multidisciplinary psychotropic review in people with dementia who lived in nursing homes. The review was associated with minimal change in prescribing of any class of psychotropic drug, although interpretation is limited by movement of participants into and out of the intervention group.

Psychotropic polypharmacy among participants before and after the medication review program was reported by 3 studies.^[@zoi180173r28],[@zoi180173r30],[@zoi180173r34]^ All 3 studies report a substantial reduction in the total volume of psychotropics associated with focused psychotropic medication review.

Clinical and Patient-Related Outcomes of Psychotropic Medication Review {#H2-3-ZOI180173}
-----------------------------------------------------------------------

Several disparate clinical outcomes were measured in twelve studies ([Table 2](#zoi180173t2){ref-type="table"}).^[@zoi180173r23],[@zoi180173r24],[@zoi180173r25],[@zoi180173r26],[@zoi180173r27],[@zoi180173r28],[@zoi180173r29],[@zoi180173r30],[@zoi180173r32],[@zoi180173r33],[@zoi180173r34],[@zoi180173r42]^ Ballard et al^[@zoi180173r23]^ reported significantly more neuropsychiatric symptoms at 9-month follow-up in people with dementia receiving antipsychotic review compared with controls (group difference in Neuropsychiatric Inventory score, 7.37; 95% CI, 1.53-13.22). Furthermore, people receiving the intervention demonstrated a nominal worsening in health-related quality of life (measured with the DEMQOL: Dementia Quality of Life measure), which did not reach statistical significance (group difference, 4.54; 95% CI, --9.26 to 0.19).^[@zoi180173r24]^ There was no difference in agitation, depression, or mortality between groups.

###### Clinical Outcomes of Focused Psychotropic Medication Review

  Source                                                              Clinical Outcome                                                                             Measure                                                                                                                                            Result
  ------------------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  **Randomized Clinical Trials**                                                                                                                                                                                                                                                                                      
  Ballard et al,^[@zoi180173r23]^ 2016                                Neuropsychiatric symptoms                                                                    Neuropsychiatric Inventory                                                                                                                         Difference between intervention and control groups favors control 7.37 (95% CI, 1.53-13.22; *P* = .02)[^a^](#zoi180173t2n1){ref-type="table-fn"}
  Agitation                                                           Cohen-Mansfield Agitation Inventory                                                          Difference between intervention and control groups: 4.60 (95% CI, −1.43 to 10.63; *P* = .13)                                                       
  Depression                                                          Cornell Scale for Depression in Dementia                                                     Difference between intervention and control groups: −1.70 (95% CI, −4.29 to 0.90; *P* = .19)                                                       
  Mortality                                                           Death                                                                                        OR, 0.67 (95% CI, 0.39-1.14; *P* = .15)                                                                                                            
  Ballard et al,^[@zoi180173r24]^ 2017                                Proxy health-related quality of life                                                         DEMQOL: Dementia-Related Quality of Life measure                                                                                                   Difference between intervention and control groups: 4.54 (95% CI, −9.26 to 0.19; *P* = .06)
  Moncrieff et al,^[@zoi180173r25]^ 2016                              Clinical symptoms of severe mental illness                                                   Brief Positive and Negative Syndrome Scale                                                                                                         Difference between intervention and control groups: 0.13 (95% CI, −2.20 to 2.48)
  Antipsychotic drug adverse effects                                  Liverpool University Neuroleptic Side-Effect Rating Scale                                    Difference between intervention and control groups: −0.42 (95% CI, −8.12 to 7.29)                                                                  
  Medication adherence                                                Medication Adherence Questionnaire                                                           Difference between intervention and control groups favors intervention: −0.44 (95% CI, −0.76 to −0.11)[^a^](#zoi180173t2n1){ref-type="table-fn"}   
  Confidence in participating in clinical discussions and decisions   Decision Self-Efficacy Scale                                                                 Mean difference between intervention and control group: −4.16 (95% CI, −9.81 to 1.49)                                                              
  Patient satisfaction                                                Client Satisfaction Questionnaire                                                            Difference between intervention and control groups: −0.29 (95% CI, −3.04 to 2.45)                                                                  
  Attitude toward medication                                          Drug Attitude Inventory                                                                      Difference between intervention and control groups: 1.65 (95% CI, −0.09 to 3.40)                                                                   
  Jordan et al,^[@zoi180173r26]^ 2015                                 Drug-related problems addressed (adverse effects)                                            Counts                                                                                                                                             Difference between intervention and control groups favors intervention: 3.34 (95% CI, 2.57-4.11; *P* \< .001)[^a^](#zoi180173t2n1){ref-type="table-fn"}
  Functional ability                                                  Bristol Activities of Daily Living Scale                                                     Mean difference between intervention and control group: 0.45 (95% CI, −0.47 to 0.93; *P* = .52)                                                    
  Dementia psychopathology                                            Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia   Difference between intervention and control groups: 4.67 (95% CI, −0.04 to 2.78; *P* = .06)                                                        
  Patterson et al,^[@zoi180173r27]^ 2010                              Falls                                                                                        Rate                                                                                                                                               16.3 falls/100 person-mo in intervention group vs 11.4 falls/100 person-months in control group (*P* = .09)
  **Before-After Study Designs**                                                                                                                                                                                                                                                                                      
  Gallimore et al,^[@zoi180173r42]^ 2016                              Up-to-date laboratory monitoring                                                             Proportion of participants                                                                                                                         54.1% (before); 72.1% (after) (*P* \< .001)[^a^](#zoi180173t2n1){ref-type="table-fn"}
  At risk of drug-drug interaction                                    Proportion of participants                                                                   43.8% (before); 24.3% (after) (*P* \< .001)[^a^](#zoi180173t2n1){ref-type="table-fn"}                                                              
  Movement adverse effect monitoring                                  Proportion of participants                                                                   75.0% (before); 63.5% (after) (*P* = .21)                                                                                                          
  Branford,^[@zoi180173r29]^ 1996                                     Clinical presentation                                                                        Subjective assessment                                                                                                                              25% undergoing medication change had "good" outcome, 43% "poor" outcome, 32% "unclear" outcome
  Jauernig et al,^[@zoi180173r34]^ 1995                               Challenging behavior                                                                         Frequency counts                                                                                                                                   Mean daily frequency of challenging behavior lower after the intervention than at baseline in 80%
  Bisconer et al,^[@zoi180173r28]^ 1995                               Challenging behavior                                                                         Frequency counts                                                                                                                                   Mean decrease in challenging behavior after intervention
  Reported medication adverse effects                                 Proportion of participants                                                                   (n = 11 \[14%\]) before intervention, (n = 8 \[10%\]) after intervention                                                                           
  Glaser et al,^[@zoi180173r32]^ 1986                                 Aggressive challenging behavior                                                              Frequency counts                                                                                                                                   No significant difference between intervention and control groups[^b^](#zoi180173t2n2){ref-type="table-fn"}
  Inoue,^[@zoi180173r33]^ 1982                                        Clinical presentation                                                                        Subjective assessment                                                                                                                              "Positive change" in 96.5% receiving intervention, "negative" change in 3.5%
  Ellenor et al,^[@zoi180173r30]^ 1977                                Challenging behavior                                                                         Aberrant Behavior Checklist                                                                                                                        "Slight increase" in challenging behavior but no significant difference between intervention and control group[^b^](#zoi180173t2n2){ref-type="table-fn"}

Abbreviation: OR, odds ratio.

Results statistically significant at *P* \< .05.

These studies had control groups only for the secondary outcome of change in challenging behavior.

The medication review intervention tested by Moncrieff et al^[@zoi180173r25]^ was co-designed with people with severe mental illness with the aim of increasing patient involvement and agency in decision making regarding antipsychotics. There was no difference in scores on the Decision Self-Efficacy Scale between those randomized to receive the intervention and those receiving treatment as usual, suggesting that the focused psychotropic medication review did not improve patients' confidence in discussions or decisions about psychotropic medication. Those in the review group demonstrated a tendency to greater medication adherence but no significant difference was found in other secondary outcome measures of patient satisfaction, attitude toward psychotropic drugs, symptoms of psychosis, or adverse effects of antipsychotic drugs between groups at follow-up 2 to 4 weeks after the review meeting. However, fidelity of implementation was poor and the study tested only feasibility and therefore was not powered to detect effect sizes.

Jordan et al^[@zoi180173r26]^ reported that more medication-related problems were identified and addressed with nurse-led medication review than without. There was no significant difference in change in psychopathologic characteristics of dementia, behavior changes, or functional ability between groups during the study period. Longer-term outcomes on patient health or well-being were not assessed.

Patterson et al^[@zoi180173r27]^ measured the rate of falls in a group of individuals with dementia who needed a high level of care. The reductions in inappropriate psychotropic drug use in the intervention group vs the control group did not translate to a difference in the rate of falls between groups (11.4 falls per 100 person-months in the control group vs 16.3 falls per 100 person-months in intervention group; *P* = .09), although the method of recording falls was subject to inaccuracies and the authors note that the study was underpowered.

Gallimore et al^[@zoi180173r42]^ reviewed the potential for a focused psychotropic medication review by a remote pharmacist, conducted several weeks after out-patient psychiatry consultation, to improve rates of routine adverse drug event monitoring. The focused psychotropic medication review was associated with an increase in the proportion of participants with up-to-date laboratory monitoring and significantly reduced the proportion of those at risk of drug-drug interactions but had no effect on the proportion of participants who were monitored for movement adverse effects. The actual benefit in terms of adverse drug event rates was not measured.

The study by Bisconer et al^[@zoi180173r28]^ was the only one, to our knowledge, to report rates of adverse drug events, albeit with a basic and unvalidated method. The proportion of the cohort with any physician-observed adverse effect decreased from 14% at baseline to 10% after the review program, but the small number of participants is a major limitation of this study.

Four studies report change in challenging behavior as a result of antipsychotic review and reduction programs in institutions for people with intellectual disability.^[@zoi180173r28],[@zoi180173r30],[@zoi180173r32],[@zoi180173r34]^ These studies report a decrease or no change in challenging behavior associated with the delivery of the program. The authors concluded that many psychotropic drugs given in this population can be stopped without causing further deterioration in behavior.

Economic Outcomes of Psychotropic Medication Review {#H2-4-ZOI180173}
---------------------------------------------------

Five studies^[@zoi180173r26],[@zoi180173r30],[@zoi180173r36],[@zoi180173r44],[@zoi180173r45]^ reported descriptive cost data in terms of savings made after focused psychotropic medication review. None of the 5 studies conducted comprehensive economic evaluation (eTable 3 in the [Supplement](#note-ZOI180173-1-s){ref-type="supplementary-material"}).

Discussion {#H1-4-ZOI180173}
==========

Psychotropic medication plays a central role in the treatment of mental disorders, yet remains the subject of debate. Treatment benefits must be balanced against adverse drug events, which are both common and distressing.^[@zoi180173r50]^ Rising rates of prescription of psychotropic drugs are observed worldwide, despite the modest effect size of these medications for most indications^[@zoi180173r51]^ and the increasing availability of and evidence for nonpharmacologic interventions. From an economic perspective, the estimated US annual expenditure on psychotropic drugs of \$30 billion^[@zoi180173r52]^ must be viewed in the context of nonadherence rates of up to 65%,^[@zoi180173r53]^ which contributes to significant waste of health care resources. On a personal level, patient views and preferences should be respected, but many report feeling disempowered and excluded from decisions about psychotropic medication.^[@zoi180173r54]^ Medication optimization aims to address these tensions through a variety of strategies, including medication review.

Our review of the literature shows that programs of focused psychotropic medication review have attracted ongoing interest and have been instituted across different settings during the past 4 decades. There is considerable diversity in how focused psychotropic medication review has been delivered.

Meta-analysis of 3 RCTs demonstrated a significantly greater likelihood of psychotropic drug reduction with focused psychotropic medication review than with treatment as usual in elderly individuals with dementia living in nursing homes.^[@zoi180173r23],[@zoi180173r26],[@zoi180173r27]^ Results from several uncontrolled before-after studies seem to support this finding by reporting an association between medication review and change in drug prescribing, irrespective of participant group. This finding indicates potential for improved prescribing after medication review and, although it seems logical that a change in medication after a critical evaluation will be beneficial, the clinical gains after focused psychotropic medication review cannot be assumed. Many studies did not measure benefits (or harms) associated with medication review. A change in drug prescribing is an intermediary outcome that offers only a crude measure of medication optimization; only 1 study objectively assessed medication appropriateness against consensus guidelines.^[@zoi180173r27]^ One RCT reported identification of a greater number of adverse drug events as a result of focused psychotropic medication review, but not the resolution of these adverse events.^[@zoi180173r26]^ Two RCTs failed to demonstrate any benefit of medication review on clinically meaningful parameters^[@zoi180173r25],[@zoi180173r27]^ and 1 RCT reported deterioration in patients' neuropsychiatric symptoms after medication review and subsequent reduction in drug prescribing.^[@zoi180173r23],[@zoi180173r24]^

The medication optimization approach is intrinsically patient-centric^[@zoi180173r55]^ and medication review can provide an opportunity to explore patient beliefs and preferences and to reach shared treatment decisions. However, with 1 notable exception,^[@zoi180173r25]^ our review highlights a major lack of patient input and personalization in existing focused psychotropic medication reviews, which represents a significant barrier to achieving true medication optimization. This finding may reflect the age of several of the studies and a prevailing paternalism in medication decision making in those prescribed psychotropic drugs.^[@zoi180173r56]^

The potential for financial savings is a strong motivator for medication optimization, yet investigation of the economic implications and resource use of psychotropic medication review has largely been neglected. Any cost savings from reductions in prescribing and avoidance of adverse drug events must be offset against the initial outlay of performing the medication review, additional activity generated (eg, referrals to another health care professional or increased monitoring mandated by drug changes), and switches to more expensive drugs or preparations. In these terms, our findings support calls for more attention to be paid to economic evaluation of medication review.^[@zoi180173r57],[@zoi180173r58]^

Most of the studies included in our review were conducted in elderly individuals, people with dementia, or adults with intellectual disability, in many cases residing in institutional facilities. People in these groups are at high risk of suboptimal psychotropic use and overuse and may lack the capacity to consent to treatment decisions, yet their underrepresentation in controlled clinical trials leads to a lack of empirical evidence and data-driven prescribing guidelines. Individual regular and pragmatic psychotropic medication review may have the most to offer to these groups, where advantages of medications are less well established and adverse effects are common and idiosyncratic. However, to realize this potential, the quality and reproducibility of future studies must be improved. Although recent studies are more robust methodologically, the overall risk of bias is high, with limitations conferred by both study design and reporting. Future trials should ensure standardized reporting of the intervention (eg, using the TIDieR \[Template for Intervention Description and Replication\] checklist^[@zoi180173r59]^) and address the feasibility and acceptability of medication review interventions, as their implementation in routine care may be complex^[@zoi180173r25]^ and they may not always be welcomed by patients or their caregivers.^[@zoi180173r60]^ Moreover, inconsistencies in terminology should be resolved and the concept of medication review clearly delineated from other attempts to optimize psychotropic prescribing.^[@zoi180173r61],[@zoi180173r62]^

Data in the included studies were not sufficiently detailed to enable subgroup analysis of medication reviews, beyond grouping interventions by one-off medication review and ongoing review programs. Multidisciplinary review programs, conducted mostly with participants with intellectual disability living in institutional care, tended to be associated with the greatest proportion of participants changing medication, although this finding could be a function of the high level of psychotropic use in this group.^[@zoi180173r63]^

There is no universally accepted standard procedure for medication review.^[@zoi180173r16],[@zoi180173r64],[@zoi180173r65]^ Although best practice advice and consolidated tools have been developed to guide medication review^[@zoi180173r66],[@zoi180173r67]^ and define potentially inappropriate prescribing,^[@zoi180173r68],[@zoi180173r69],[@zoi180173r70]^ few of the medication reviews were informed by a theoretical model. There is the potential for electronic mechanisms, including e-prescribing and the electronic patient record, to support medication review, in a way which does not yet seem to have been investigated fully.^[@zoi180173r71]^

Our findings do not suggest a professional discipline that should lead psychotropic medication review, although third-party reviews by a professional (usually a pharmacist) external to the usual team might be difficult to embed in routine care. As few as one-third of medication recommendations made by pharmacists are actioned by prescribers,^[@zoi180173r37]^ and nonprescribers conducting reviews often report lacking influence,^[@zoi180173r72]^ highlighting the importance of good interprofessional communication in complex medication review interventions.

Existing studies and reviews that evaluate the effect of medication review (in other populations and focused on other drug types) similarly conclude that medication review can influence proximal medication-related outcomes but demonstrate weak evidence of benefit in clinical and patient outcomes.^[@zoi180173r66],[@zoi180173r67],[@zoi180173r73],[@zoi180173r74]^ Despite this finding, medication review is recommended by guidelines as part of routine care for several groups at high risk of suboptimal prescribing and adverse drug events, including elderly individuals, those with chronic conditions, and those receiving polypharmacy.^[@zoi180173r16],[@zoi180173r75]^

This systematic review and meta-analysis was of focused psychotropic medication review. As an isolated intervention, focused medication review has limitations. Comprehensive medication review, in which all medications are reviewed simultaneously regardless of indication, can highlight drug-drug interactions that might be missed by focusing on psychotropics alone. In practice, however, psychotropic drug prescribing is often performed by specialists who may not feel equipped to review medication for physical health conditions. A treatment review that also incorporates response to nonpharmacologic interventions is attractive, but might be difficult to protocolize where treatment aims span different dimensions.

Strengths and Limitations {#H2-5-ZOI180173}
-------------------------

To our knowledge, this is the first systematic review to synthesize the evidence for focused psychotropic medication review. We applied few limits to the search and included varied study designs. We identified several additional articles through hand searches; this approach is likely to reflect the nebulous nature of the intervention and a lack of consistent terminology, as well as poor indexing of older studies. Members of the research team independently appraised studies against prespecified inclusion criteria and judged study quality using published frameworks. We conducted meta-analysis and calculated pooled effects where possible.

The deficits of the primary literature limit the strength of our conclusions about the benefits of psychotropic medication review. Most studies included were uncontrolled and prone to bias and confounding, and it is difficult to attribute causality in before-after designs. It is impossible to blind participants and practitioners to the intervention, although blinding might not be essential where outcomes (eg, prescribing rates) are objective. Clinical outcomes of medication review may only become apparent after some time; thus, the limited follow-up in the included studies is a major problem. Diversity in outcome measures and reporting precluded more extensive meta-analysis. There is potential for publication bias to skew the results of this review and there were insufficient data to assess this risk statistically. We did not search the gray literature.

Conclusions {#H1-5-ZOI180173}
===========

Focused psychotropic medication review as a structured and critical evaluation of a patient's drug therapy has the potential to contribute to medication optimization. Despite much attention and incorporation into routine care, the evidence for focused psychotropic medication review as a stand-alone intervention is weak and it has not been shown that changes in psychotropic prescribing associated with focused psychotropic medication review translate to improved clinical and patient-important outcomes. High-quality research is essential before a routine program of focused psychotropic medication review can be recommended, either in general or special populations. Standardization of nomenclature, processes, and an agreed common set of outcomes that prioritizes patient-important measures is needed. This might be achieved with the creation of a national or international collaborative medication review research network.
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